Reports that Cubist Pharmaceuticals has announced that its antibiotic, Cidecin, has failed to meet the statistical endpoint in a phase 3 trial for the treatment of community-acquired pneumonia. Decline in the company's share price; Reasons cited for the failure of Cidecin; Attractions in antibiotic drug discovery for pharmaceutical firms.